

NEWS**FOR IMMEDIATE RELEASE**

Clinical Data Inc. Signs Exclusive License for Monoclonal Antibody Pharmacogenetic Patent Portfolio

Clinical Data to Commercialize Novel Test For Response to Treatment for non-Hodgkin's Lymphoma

NEWTON, Mass. – October 18, 2006 – Clinical Data Inc. (NASDAQ: CLDA) announced today that it has signed an exclusive worldwide license to an extensive portfolio of patents related to a variation in the Fc gamma receptor IIIA gene. Clinical Data's intent is to develop a Therapeutic Diagnostic™ for response to rituximab (Rituxan®, Genentech/Biogen-Idec and Mabthera®, Hoffmann-La Roche) in the treatment of non-Hodgkin's Lymphoma (NHL). Rituximab is approved for use in the treatment of NHL and rheumatoid arthritis (RA). It is expected that variation in this gene will also play an important role in determining response to other monoclonal antibodies for the treatment of Crohn's disease, rheumatoid arthritis and other inflammatory diseases. These are high-cost disease areas and fit Clinical Data's model of commercializing proprietary pharmacogenetic tests that will improve patient outcomes while reducing overall healthcare costs.

Published research indicates that a pharmacogenetic test based on variation in the FCGR3A gene will have specificity of over 90% for predicting response to rituximab in NHL.¹ This test will help physicians determine who is most likely to respond to rituximab allowing a more targeted therapeutic approach. In treating NHL, rituximab is typically used as a component of combination therapy in conjunction with one or more of approximately 50 different drugs. Treatment options for NHL include single-agent and combination chemotherapy, chemo-immunotherapy (such as rituximab), and radio-immunotherapy.

Drew Fromkin, President and CEO, said, "A pharmacogenetic test for rituximab response will assist physicians, patients and payers in deciding the appropriate treatment for some very costly and life-threatening diseases. This license presents another tremendous opportunity to advance our mission with Therapeutic Diagnostics and to ensure the use of the safest and most efficacious drugs, while reducing costs for healthcare payers worldwide. We look forward to launching the test in the first calendar quarter of 2007."

About Non-Hodgkin's Lymphoma

Lymphoma is a general term for cancers that develop in the lymphatic system. Hodgkin's disease is one type of lymphoma; other lymphomas are grouped together as non-Hodgkin's lymphoma. Lymphomas account for about 5% of all cases of cancer in this country according to the National Cancer Institute. The American Cancer Society estimates that 54,390 new cases of NHL were diagnosed in 2005 in the United States. NHL affects 1.5 million people worldwide and has grown in incidence by 80% since the early 1970s².

About Clinical Data, Inc.

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth™; Cogenics™; and Vital Diagnostics™. The Pharmacogenomics and Molecular Services™ division, Cogenics, consolidates operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc., Icoria, Inc., and Genome Express SA to provide a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. PGxHealth builds upon

existing assets and know-how acquired from Genaisance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth develops, validates and commercializes novel Therapeutic Diagnostics™, in some instances in combination with new and existing therapeutics, to improve patient care. In addition, PGxHealth has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide. With a focus on the physician's office, hospital and small-to-medium sized laboratory segments and customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data is headquartered in Newton, Mass. with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward-looking statements. *These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.*

Internet Website: www.clda.com

For More Information

Investors:

John Quirk
1-646-536-7029
jquirk@theruthgroup.com

Media:

Janine McCargo
1-646-536-7033
jmccargo@theruthgroup.com

¹ Cartron G, Dacheux L, Salles G, Solal-Celigny P., Bardos P., Colombat P., Watier H. Blood. 99: 754-8, 2002

² World Health Report 2000, World Health Organization, www.who.int